IPO mania evaporates in Hong Kong

Global Economy

TBS Report
20 March, 2021, 10:25 pm
Last modified: 20 March, 2021, 10:31 pm
Volatility sparked by the great rotation into previously unloved stocks sensitive to economic fluctuations from loftily valued tech and health-care plays is to blame, according to investors

The days of the massive first-day booms in Hong Kong's initial public offering (IPO) frenzy may be nearing an end, according to Bloomberg.

Even as the pandemic spread for most of 2020, the offshore Chinese city's IPOs and new listings were in hot demand from both institutional and mom-and-pop investors. With the bulk of new share sales posting large gains on their first-day of trading, investor euphoria was justified.

That was then. Last year's largely winning investor play of piling into IPOs and exiting after they debuted is no longer a slam dunk. Almost 31% of thirteen IPOs raising more than $100 million posted losses on day one this year, almost double the 17% in 2020. A median first-day move showed gains of 2.1% in 2021 from 5.7% last year, according to data compiled by Bloomberg.

Volatility sparked by the great rotation into previously unloved stocks sensitive to economic fluctuations from loftily valued tech and health-care plays is to blame, according to investors. Others also pointed to worries about policy being tightened in China as weighing on investors' risk appetite for new stock.

"Most IPOs performed really, really strongly last year, but I'm not expecting that kind of movement this year," said Joohee An, a fund manager at Mirae Asset Global Invest (HK) Ltd. Investors will be "more prudent" as market liquidity "won't be as abundant as it used to be", she added.

To be clear, listings by Kuaishou Technology and New Horizon Health Ltd. still did unusually well in February, with shares more than doubling on the first day.

But lukewarm post-listing performances are increasing. Chinese household insecticide company Cheerwin Group Ltd slumped as much as 20% on its first trading day last week. Biopharmaceutical company SciClone Pharmaceuticals Holdings Ltd ended its 3 March debut flat and is now trading 8.6% below its offer price.

The secondary listing wave of US-listed Chinese companies hasn't always had glowing debuts in Hong Kong. Autohome Inc, a Chinese online car-sales website with its primary listing in New York, ended its Hong Kong debut on Monday with a modest 2% rise.

Not everyone is concerned, given rising concerns voiced by some that global markets were in bubble territory.

"When you have these deals that don't do well, it actually tells you that people are still being cautious about what they're investing in and what they're not, which is a good sign," said Sumeet Singh, head of research at Aequitas Research in Singapore, who publishes on Smartkarma. "It means the market is doing OK."

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.